Broad, growing pipeline of first-
and best-in-class therapies
Broad, growing pipeline of first-
and best-in-class therapies
Broad, growing pipeline
of first- and best-in-class
therapies
We aim to address common medical challenges that arise as we age, focusing first on acute diseases with high unmet need
Muscle Aging
Immune Aging
Brain Aging
Portfolio strategy
A human-first approach at the intersection of known and novel aging biology
With the high throughput and diversity of targets from our platform, we are able to address disease of aging through multiple independent and orthogonal mechanisms
Areas of focus
Immune aging
Muscle aging
Brain aging
As we age, our natural immune defenses remain active even when not fighting infection, leading to chronic inflammatory states that degrade tissue, interfere with organ function, and drive diseases in the brain, eye, and throughout the body.
Our immune aging program defuses pathologic inflammation, restoring youthful regulation of cytokine responses and slowing or reversing disease progression.
As they age, muscles lose mass, strength, and the ability to regenerate. In older people, the resultant frailty dramatically decreases mobility, independence, and quality of life, and hinders recovery from injury.
Our muscle aging programs pursue orthogonal mechanisms to preserve or restore muscle function, enabling patients to maintain physical function and separating the process of growing older from disability and disease.
Brain aging drives debilitating disease processes that span neurosensory loss, cognitive impairment, and neurodegeneration. All interfere with daily activities, raise the risk of social isolation, and decrease quality of life.
Our longitudinal human aging cohorts provide novel insight into early drivers of brain aging, providing opportunities to delay or prevent these highly prevalent and highly morbid disease processes and allow older people to maintain independence and continue enjoying their lives
Immune aging
As we age, our natural immune defenses remain active even when not fighting infection, leading to chronic inflammatory states that degrade tissue, interfere with organ function, and drive diseases in the brain, eye, and throughout the body.
Our immune aging program defuses pathologic inflammation, restoring youthful regulation of cytokine responses and slowing or reversing disease progression.
Muscle aging
As they age, muscles lose mass, strength, and the ability to regenerate. In older people, the resultant frailty dramatically decreases mobility, independence, and quality of life, and hinders recovery from injury.
Our muscle aging programs pursue orthogonal mechanisms to preserve or restore muscle function, enabling patients to maintain physical function and separating the process of growing older from disability and disease.
Brain aging
Brain aging drives debilitating disease processes that span neurosensory loss, cognitive impairment, and neurodegeneration. All interfere with daily activities, raise the risk of social isolation, and decrease quality of life.
Our longitudinal human aging cohorts provide novel insight into early drivers of brain aging, providing opportunities to delay or prevent these highly prevalent and highly morbid disease processes and allow older people to maintain independence and continue enjoying their lives
Indication strategy
Disease-first focus with an emphasis on early de-risking
Broader aging indications:
- Evidence build over time may allow drugs to be used at the population level (e.g., statins)
Disease-first focus ($B+ opportunities):
- Treating disease by targeting key aging pathways
- High unmet need & market opportunity
- Clear development & regulatory paths
Program de-risking:
- Initial indications have an efficient path to POC and commercialization
